{ "Imaging Inflammation in Brain Cancers with [C-11]-CS1P1", "This study is looking at how a special imaging agent called [C-11]-CS1P1 (an S1P1 PET imaging agent) can help us understand inflammation in primary (starting in the brain) and secondary (spread to the brain) central nervous system cancers. Researchers want to see how this agent shows up in tumors compared to normal brain tissue. You might be able to join if you are an adult (18 or older) with a confirmed diagnosis of primary or secondary central nervous system cancer that hasn't been treated with radiation yet. The main goal is to measure how much of the [C-11]-CS1P1 agent is taken up by the tumor compared to healthy brain tissue. This study is currently recruiting 104 participants.", "design": "This is an interventional imaging study that will include 104 adult participants. It is a single-arm study, meaning all participants will receive the same intervention.", "commitments": "You would undergo a baseline [C-11]-CS1P1 PET scan and may have an optional Brain MRI. You will also be invited for a follow-up [C-11]-CS1P1 PET scan within 24 months of the first scan, ideally around 6 months after treatment.", "compensation": "Not stated in the trial record.", "follow_up": "Participants will have a follow-up scan within 24 months of their baseline scan, preferably within 6 months after treatment.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.